IRIS
AURIEMMA, RENATA SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.113
AS - Asia 4.954
EU - Europa 3.085
SA - Sud America 622
Continente sconosciuto - Info sul continente non disponibili 188
AF - Africa 115
OC - Oceania 6
Totale 14.083
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.904
SG - Singapore 2.153
RU - Federazione Russa 1.501
CN - Cina 1.011
VN - Vietnam 850
BR - Brasile 474
IT - Italia 440
HK - Hong Kong 398
DE - Germania 236
FR - Francia 163
SE - Svezia 155
FI - Finlandia 138
BD - Bangladesh 125
CA - Canada 114
NL - Olanda 110
GB - Regno Unito 84
IN - India 78
IE - Irlanda 74
AR - Argentina 64
UA - Ucraina 63
JP - Giappone 56
MX - Messico 45
KR - Corea 37
IQ - Iraq 33
EC - Ecuador 27
TH - Thailandia 27
ZA - Sudafrica 26
CI - Costa d'Avorio 25
PL - Polonia 25
PH - Filippine 21
TR - Turchia 21
ES - Italia 20
CO - Colombia 18
TW - Taiwan 17
ID - Indonesia 16
KE - Kenya 16
PK - Pakistan 16
AT - Austria 14
IR - Iran 13
VE - Venezuela 12
EG - Egitto 11
LT - Lituania 10
UZ - Uzbekistan 10
BE - Belgio 9
JM - Giamaica 9
MA - Marocco 9
AE - Emirati Arabi Uniti 8
CL - Cile 8
IL - Israele 8
PY - Paraguay 8
CZ - Repubblica Ceca 7
OM - Oman 7
JO - Giordania 6
SA - Arabia Saudita 6
CH - Svizzera 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
GT - Guatemala 5
LB - Libano 5
MY - Malesia 5
TN - Tunisia 5
UY - Uruguay 5
CR - Costa Rica 4
PA - Panama 4
PT - Portogallo 4
RO - Romania 4
SY - Repubblica araba siriana 4
AL - Albania 3
AZ - Azerbaigian 3
BO - Bolivia 3
HN - Honduras 3
NI - Nicaragua 3
PE - Perù 3
PR - Porto Rico 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BS - Bahamas 2
EE - Estonia 2
ET - Etiopia 2
GA - Gabon 2
GM - Gambi 2
HU - Ungheria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LC - Santa Lucia 2
LK - Sri Lanka 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PF - Polinesia Francese 2
QA - Qatar 2
RW - Ruanda 2
SN - Senegal 2
SV - El Salvador 2
TL - Timor Orientale 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AI - Anguilla 1
Totale 13.867
Salva come PNG Salva come JPEG
Città #
Singapore 1.029
San Jose 1.005
Hong Kong 387
Moscow 381
Chandler 369
Ashburn 350
Beijing 300
Ho Chi Minh City 269
Hanoi 196
Santa Clara 172
Hefei 166
The Dalles 144
Naples 133
Los Angeles 114
Munich 103
Lauterbourg 101
Millbury 98
Amsterdam 93
Princeton 72
Jacksonville 71
New York 66
Nanjing 59
Boston 53
Wilmington 51
Dallas 50
São Paulo 49
Tokyo 48
Buffalo 45
Redondo Beach 43
Da Nang 38
Helsinki 38
Ottawa 38
Seattle 37
Frankfurt am Main 36
Napoli 36
Woodbridge 32
Orem 31
Turku 31
Council Bluffs 29
San Francisco 29
Des Moines 28
Houston 28
Montreal 28
Seoul 27
Chicago 26
Atlanta 25
Denver 23
Toronto 23
Haiphong 22
Falls Church 21
Phoenix 21
Rome 21
Warsaw 21
Falkenstein 20
Mexico City 20
Hebei 19
Milan 18
Nairobi 16
Nanchang 16
Shenyang 15
Stockholm 15
Baghdad 14
Lawrence 14
Nuremberg 14
Brooklyn 13
Changsha 13
Chennai 13
Dublin 13
London 13
Quito 13
Rio de Janeiro 13
Ann Arbor 12
Johannesburg 12
Shanghai 12
Ardabil 11
Biên Hòa 11
Dhaka 11
Hải Dương 11
Jiaxing 11
Manchester 11
Tianjin 11
Ankara 10
Bangkok 10
Boydton 10
Curitiba 10
Guangzhou 10
Augusta 9
Kronberg 9
Miami 9
Poplar 9
Porto Alegre 9
San Mateo 9
Thái Nguyên 9
Boardman 8
Bologna 8
Can Tho 8
Charlotte 8
Mumbai 8
Salvador 8
Tashkent 8
Totale 7.260
Salva come PNG Salva come JPEG
Nome #
Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial 512
Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas 237
Medical consequences of acromegaly: what are the effects of biochemical control? 222
Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age 180
Effect of the acute administration of the Dopamine Agonist Cabergoline on glucose tolerance and Insuline Sensitivity in patient with obesity. 176
The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study 173
The association of fasting insulin concentrations and colonic neoplasms in acromegaly: a colonoscopy-based study in 210 patients 172
Low prolactin level identifies hypoactive sexual desire disorder women with a reduced inhibition profile 172
Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. 166
Severe systemic complications of acromegaly 162
Bisphenol A: An emerging threat to female fertility 162
Circulating myomiRNAs as biomarkers in patients with Cushing's syndrome 158
Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: A retrospective, comparative, head-to-head study 156
The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. 154
Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. 153
Hypertension in acromegaly and in the normal population: prevalence and determinants 151
The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma 149
Investigational drugs for the treatment of acromegaly: new agents to transform therapy 148
The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center. 147
Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly 147
Fertility in Acromegaly: a single center experience on female patients during active disease and after disease remission 145
Acromegaly and the cardiovascular system 145
Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. 144
Impact of Somatostatin Analogs vs. Surgery on glucose metabolism in acromegaly: Results of a 5 years observational, open, prospective study 141
New perspectives in the medical treatment of acromegaly 141
Cabergoline counteracts adipose and skeletal muscle lipid accumulation: A novel therapeutic approach to obesity? 140
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group 140
Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit 140
Erratum to: The treatment with pasireotide in Cushing’s disease: effects of long–term treatment on tumor mass in the experience of a single center (Endocrine, (2015), 50, (725-740) DOI 10.1007/s12020-015-0557-2) 139
The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology 139
Adverse events associated with somatostatin analogs in acromegaly. 138
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance 138
Effect of Cabergoline on Metabolism in Prolactinomas. 137
The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission. 136
Mediterranean Diet: What Are the Consequences for Menopause? 135
Growth hormone nadir during oral glucose load depends on waist circumference, gender and age: normative data in 231 healthy subjects. 135
The Vaginal Microbiome: A Long Urogenital Colonization Throughout Woman Life 135
Effect of Chronic Cabergoline Treatment and Testosterone Replacement on Metabolism in Male Patients with Prolactinomas 134
Approach to the Patient with Prolactinoma 133
An evaluation of patients with hyperprolactinemia: have dynamic tests had their day? 133
Complete disappearance of a GH-secreting pituitary macroadenoma in a patient with acromegaly: effect of treatment with lanreotide Autogel and consequence of treatment withdrawal. 133
Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly 132
Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma 130
Prolactin effects on the pathogenesis of diabetes mellitus 125
Cardiometabolic effects of hypoprolactinemia 123
Effects of initial therapy for five years with somatostatin analogs foracromegaly on growth hormone and insulin-like growth factor-I levels, tumorshrinkage, and cardiovascular disease: a prospective study. 123
Metabolic effects of prolactin 123
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting 122
Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center 120
Somatostatin analogs in the clinical management of pituitary neoplasms 120
Global psychological assessment with the evaluation of life and sleep quality and sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study 119
Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. 119
Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. 119
Cardiovascular disease in Cushing's syndrome: heart versus vasculature. 118
PER2 expression and cellular localization play a critical role in tumor aggressiveness and drug resistance in an in vitro model of hepatocellular carcinoma 117
Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment 117
Risk Assessment of Diabetes Mellitus during and after Pregnancy in Women with Prolactinomas 116
A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients 116
Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study 115
The environment and male reproductive system: the potential role and underlying mechanisms of cadmium in testis cancer 114
Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study 114
Glycometabolic control in Acromegalic patients with Diabetes: a study of the effects of different treatments for GH excess and for hyperglycaemia. 114
Treatment with GH receptor antagonist in acromegaly:effect on cardiac arrhythmias. 114
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms 114
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients 112
Early Left Ventricular Diastolic Dysfunction in Females with Chronic Hyperprolactinemia: A Doppler Echocardiographic Study 110
Efficacy and tolerability of treatment with pegvisomant in acromegaly: An overview of literature 109
Metabolic syndrome in the era of COVID-19 outbreak: impact of lockdown on cardiometabolic health 109
Erratum to: Pituitary tumors and pregnancy: The interplay between a pathologic condition and a physiologic status (Journal of Endocrinological Investigation (2014) 37, (99-112) DOI: 10.1007/s40618-013-0019-8) 108
Prevalence of the Metabolic Syndrome in moderately-severely obese subjects with and without Growth Hormone Deficiency. 108
The role of somatostatin receptors in the medical treatment of acromegaly 107
Acromegaly and changes in growth parameters: A focus on cardiovascular,metabolic, respiratory abnormalities, malignancies, and bone alterations 107
Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy 106
Increased risk of osteoporosis in postmenopausal women with type 2 diabetes mellitus: a three-year longitudinal study with phalangeal QUS measurements 106
Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance 105
Hyperprolactinemia after menopause: Diagnosis and management 105
Diabetes mellitus, vaginal microbiome and sexual function: Outcomes in postmenopausal women 104
The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs 104
The safety of treatments for prolactinomas 103
TREATMENT WITH GROWTH HORMONE RECEPTOR ANTAGONIST IN ACROMEGALY: EFFECT ON CARDIAC ARRHYTHMIAS. 102
Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). 102
Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly 99
Glucose abnormalities associated to prolactin secreting pituitary adenomas 99
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. 98
Microalbuminuria in insulin sensitivity in patients with growth hormone-secreting pituitary tumor 97
Pituitary carcinomas. 97
Clinical and genetic characterization of pituitary gigantism: An international collaborative study in 208 patients 96
Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs 95
Effects of the metabolic syndrome (METS) on gonadal function and sperm parameters in acromegalic patients: a retrospective analisys 92
Clinical Case 1 88
Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities 88
Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience 87
Different effect of acute administration of the dopamine agonist cabergoline on glucose tolerance and insulin sensitivity in obese pateints in relation to GH status. 87
Dopamine Agonists: From the 1970s to Today 87
Evaluation of the retinal nerve fibre layer and ganglion cell complex thickness in pituitary macroadenomas without chiasmal compression. 83
Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. 82
Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study. 80
Probiotics and Prebiotics: Any Role in Menopause-Related Diseases? 75
Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-monthstudy. 75
The Role of the Environment in Testicular Dysgenesis Syndrome 73
Totale 12.827
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.142
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.142
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022569 0 0 0 3 16 81 12 19 85 35 115 203
2022/2023819 97 89 21 66 97 90 4 69 144 98 34 10
2023/2024512 22 87 60 55 26 41 13 61 9 10 76 52
2024/20253.297 164 162 43 30 79 175 409 218 178 260 1.271 308
2025/20267.267 721 544 735 591 1.213 285 1.009 343 843 450 178 355
2026/2027747 548 199 0 0 0 0 0 0 0 0 0 0
Totale 14.083